Allergan Comes To Q3 Call With Deal News, But Nothing On Pfizer
This article was originally published in The Pink Sheet Daily
Allergan announced a licensing deal with Mimetogen to commercialize a TrkA agonist for the treatment of dry eye disease, coinciding with its third quarter earnings call and R&D day, but avoided discussion of the elephant in the room.
You may also be interested in...
Allergan agreed to pay $250 million up front for global rights two investigational oral CGRP antagonists in early clinical development for acute treatment and prevention of migraine. Several rivals are racing to develop injectable CGRP antibodies.
Chief operating officer Christina Rossi talked to Scrip about the company’s new blockbuster-sized commercial opportunity for Ayvakit and the company’s next phase: financial sustainability.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.